Amp Volatility Score
Catalyst Info & Data Links
TITLE: Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) - Phase 2
ClinicalTrial.gov (NCT04003974): Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)
WHAT IS THE NEXT CATALYST EVENT?
Full Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds.
Updated by JM
FULC, Fulcrum Therapeutics, Losmapimod, Facioscapulohumeral Muscular Dystrophy (FSHD)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post